Research on Standard for Construction of Cerebrovascular Disease Biobank

doi:10.3969/j.issn.1673-5765.2021.05.006

Abstract

Abstract:

Objective To develop construction and management standards for cerebrovascular diseases (CVD) biobank for CVD precision medicine research in China, and provide technical support for building CVD biobank that can be shared. Methods With reference to the international large-scale biobanks construction experience, and based on the standardization ideas of international organization for standardization and other institutions, a framework of standard for constructing CVD biobank in China was formulated. From the perspectives of multi-dimensions such as site facilities, equipment, operating procedures, data standard and information technology, technical requirements for constructing CVD biobank were put forward. Results According to the construction standards proposed in this article, the operation and quality management system of Tiantan Cerebrovascular Disease Biobank that is in line with international standard has been established, and a biobank resource platform for CVD clinical research, containing over 100 000 biological samples that can be collected, processed, and stored in standardized norms, has been built. Conclusions Tiantan Cerebrovascular Disease Biobank has a sufficient, diversity, and multipletime collection biological samples resource, and has realized standardized information storage, which can provide technical support for CVD precision medicine research on the docking of omics research, accurate screening, early warning, diagnosis and intervention of CVD.

Key words: Biobank; Cerebrovascular disease; Clinical research; Construction norm

摘要：

目的开发适合我国脑血管病精准医学研究的生物样本库建设及管理标准，为建设可开发共享的脑血管病生物样本库提供技术保障。方法参考国际大型生物样本库建设经验，基于国际标准化组织等机构的标准化思路，形成我国脑血管病生物样本库建设标准框架，从场地设施、设备、操作规程、数据标准、信息化等多个维度，对样本库的建设提出技术要求。结果依据本研究提出的建设标准，建立了符合国际标准的天坛脑血管病生物样本库运行及质量管理体系，建成标准化采集、处理、保藏的10万人次脑血管病临床研究生物样本资源平台。结论天坛脑血管病生物样本库具有样本量充足、多样、多时点采集的生物样本资源，并实现了标准化的信息存储，可为对接脑血管病多组学研究，脑血管病精准筛查、预警、诊断与干预等精准医学研究提供技术支撑。

关键词: 生物样本库; 脑血管病; 临床研究; 建设规范

LIN Jin-Xi, LIANG Xian-Hong,LI Shang-Zhi, LIU Li, MENG Xia, WANG Yi-Long, WANG Yong-Jun. Research on Standard for Construction of Cerebrovascular Disease Biobank[J]. Chinese Journal of Stroke, 2021, 16(05): 449-456.

林金嬉，梁宪红，李上智，刘丽，孟霞，王伊龙，王拥军. 脑血管病生物样本库建设标准研究[J]. 中国卒中杂志, 2021, 16(05): 449-456.

References

[1] 王拥军，李子孝，谷鸿秋，等. 中国卒中报告2019（中

文版）（1）[J]. 中国卒中杂志，2020，15（10）：1037-

1043.

[2] ARTENE S A，CIUREA M E，PURCARU S

O，et al. Biobanking in a constantly developing

medical world[J/OL]. Scientific World

Journal，2013：343275[2021-01-09]. https：//doi.

org/10.1155/2013/343275.

[3] 中华人民共和国国务院. 中华人民共和国人类遗传

资源管理条例[EB/OL].（2019-05-28）[2021-01-09].

http：//www.most.gov.cn/xxgk/xinxifenlei/fdzdgknr/

fgzc/flfg/201906/t20190612_147044.html.

[4] 中华人民共和国国家质量监督检验总局，中国国家

标准化管理委员会. 实验室生物安全通用要求GB

19489-2008[S]. 北京：中国标准出版社，2009.

[5] 中华人民共和国国家卫生健康委员会. 医疗机构临

床实验室管理办法[EB/OL].（2006-03-06）[2021-01-

09]. http：//www.nhc.gov.cn/wjw/gfxwj/201304/f4d5

cbc861fd43bb928d6ea124f87a19.shtml.

[6] Australasian Biospecimen Network. Biorepository

Protocols[EB/OL].（2007-03）[2021-01-09]. http：//

citeseerx.ist.psu.edu/viewdoc/download;jsessionid=

DAEE75CF1575760967046114C1847221?doi=10.1.1.7

29.5883&rep=rep1&type=pdf.

[7] CHEN Z M，CHEN J S，COLLINS R，et al. China

Kadoorie biobank of 0.5 million people：survey

methods，baseline characteristics and long-term

follow-up[J]. Int J Epidemiol，2011，40（6）：1652-

1666.

[8] HARATI M D，WILLIAMS R R，MOVASSAGHI

M，et al. An introduction to starting a biobank[J/OL].

Methods Mol Biol，2019，1897：7-16[2021-01-09].

https：//doi.org/10.1007/978-1-4939-8935-5_2.

[9] IM K，GUI D，YONG W H. An introduction

to hardware，software，and other information

technology needs of biomedical biobanks[J/OL].

Methods Mol Biol，2019，1897：17-29[2021-01-09].

https：//doi.org/10.1007/978-1-4939-8935-5_3.

[10] 国家神经系统疾病临床医学研究中心，国家神经系

统疾病医疗质量控制中心，中国卒中学会医疗质量

管理与促进分会，等. 卒中临床诊疗和疾病管理核心

数据元及定义专家共识[J]. 中国卒中杂志，2020，15

（4）：416-434.

[11] WOODFIELD R，UK Biobank Stroke Outcomes

Group，UK Biobank Follow-up and Outcomes

Working Group，et al. Accuracy of patient self-report

of stroke：a systematic review from the UK biobank stroke outcomes group[J/OL]. PLoS One，2015，10

（9）：e0137538[2021-01-09]. https：//doi.org/10.1371/

journal.pone.0137538.

[12] PHIPPS M S，FAHNER J，SAGER D，et al.

Validation of stroke meaningful use measures in a

National electronic health record system[J/OL]. J Gen

Intern Med，2016，31（Suppl1）：46-52[2021-01-09].

https：//doi.org/10.1007/s11606-015-3562-5.

[13] International Organization for Standardization. ISO

15189：2012 Medical laboratories- requirements for

quality and competence[EB/OL].（2012-11）[2021-01-

09]. https：//www.iso.org/standard/56115.html.

[14] World Health Organization. Laboratory biosafety

manual，4th edition[EB/OL].（2012-11）[2020-12-21].

https：//www.who.int/publications/i/item/9789240011

311?sequence=1&isAllowed=y.

[15] International Society for Biological and

Environmental Repositories. Best practices for

repositories collection，storage，retrieval and

distribution of biological materials for research[J].

Biopreserv Biobank，2012，10（2）：79-161.

[16] ELLIOTT P，PEAKMAN T C，UK Biobank. The UK

Biobank sample handling and storage protocol for the

collection，processing and archiving of human blood

and urine[J]. Int J Epidemiol，2008，37（2）：234-

244.

[17] LI W，HU B，LI G L，et al. Heterozygote genotypes

at rs2222823 and rs2811712 SNP loci are associated

with cerebral small vessel disease in Han Chinese

population[J]. CNS Neurosci Ther，2012，18（7）：

558-565.

[18] ZHENG H W，WANG Y L，LIN J X，et al.

Circulating MicroRNAs as potential risk biomarkers

for hematoma enlargement after intracerebral

hemorrhage[J]. CNS Neurosci Ther，2012，18（12）：

1003-1011.

[19] LI J J，WANG Y L，WANG D，et al. Glycated

albumin predicts the effect of dual and single

antiplatelet therapy on recurrent stroke[J]. Neurology，

2015，84（13）：1330-1336.

[20] LI J J，WANG Y L，LIN J X，et al. Soluble CD40L is

a useful marker to predict future strokes in patients

with minor stroke and transient ischemic attack[J].

Stroke，2015，46（7）：1990-1992.

[21] LIN J X，ZHENG H W，CUCCHIARA B L，et al.

Association of Lp-PLA2-A and early recurrence

of vascular events after TIA and minor stroke[J].

Neurology，2015，85（18）：1585-1591.

[22] LI J J，ZHAO X Q，MENG X，et al. High-sensitive

C-reactive protein predicts recurrent stroke and poor

functional outcome：subanalysis of the clopidogrel

in high-risk patients with acute nondisabling

cerebrovascular events trial[J]. Stroke，2016，47（8）：

2025-2030.

[23] WANG Y L，ZHAO X Q，LIN J X，et al. Association

between CYP2C19 loss-of-function allele status

and efficacy of clopidogrel for risk reduction among

patients with minor stroke or transient ischemic

attack[J]. JAMA，2016，316（1）：70-78.

[24] LIN Y，WANG A X，LI J J，et al. Impact of glycemic

control on efficacy of clopidogrel in transient ischemic

attack or minor stroke patients with CYP2C19 genetic

variants[J]. Stroke，2017，48（4）：998-1004.

[25] LI J J，ZHAO X Q，WANG A X，et al. High-sensitive

C-reactive protein and dual antiplatelet in intracranial

arterial stenosis[J/OL]. Neurology，2018，90（6）：

e447-e454[2020-12-21]. https：//doi.org/10.1212/

wnl.0000000000004928.

[26] WANG A X，LI S Y，ZHANG N，et al. Oxidized lowdensity

lipoprotein to high-density lipoprotein ratio

predicts recurrent stroke in minor stroke or transient

ischemic attack[J]. Stroke，2018，49（11）：2637-2642.

[27] WANG A X，XU J，CHEN G J，et al. Oxidized

low-density lipoprotein predicts recurrent stroke in

patients with minor stroke or TIA[J/OL]. Neurology，

2018，91（10）：e947-e955[2020-12-21]. https：//doi.

org/10.1212/wnl.0000000000006118.

[28] PAN Y S，CHEN W Q，WANG Y L，et al. Association

between ABCB1 polymorphisms and outcomes of

clopidogrel treatment in patients with minor stroke

or transient ischemic attack：secondary analysis of a

randomized clinical trial[J]. JAMA Neurol，2019，76

（5）：552-560.

[29] WANG A X，ZHAO X Q，LI S，et al. Oxidative

lipoprotein markers predict poor functional outcome

in patients with minor stroke or transient ischaemic

attack[J]. Eur J Neurol，2019，26（8）：1082-1090.

[30] XU J，WANG A X，WANGQIN R Q，et al. Efficacy of

clopidogrel for stroke depends on CYP2C19 genotype

and risk profile[J]. Ann Neurol，2019，86（3）：419-

426.

[31] LIN J X，WANG Y L，WANG Y J，et al.

Inflammatory biomarkers and risk of ischemic stroke

and subtypes：a 2-sample Mendelian randomization

study[J]. Neurol Res，2020，42（2）：118-125.